Plasma Proteomic Analysis Distinguishes Severity Outcomes of Human Ebola Virus Disease
Arthur Viodé, Kinga K. Smolen, Benoit Fatou, Zainab Wurie, Patrick van Zalm, Mandy Kader Kondé, Balla Moussa Kéita, Richard Amento Ablam, Eleanor N. Fish, Hanno Steen
Abstract
As evidenced by the 2013-2016 outbreak in West Africa, Ebola virus (EBV) disease (EVD) poses a major global health threat. In this study, we characterized the plasma proteomes of 12 individuals infected with EBV, using two different LC-MS-based proteomics platforms and an antibody-based multiplexed cytokine/chemokine assay. Clear differences were observed in the host proteome between individuals who survived and those who died, at both early and late stages of the disease. From our analysis, we derived a 4-protein prognostic biomarker panel that may help direct care. Given the ease of implementation, a panel of these 4 proteins or subsets thereof has the potential to be widely applied in an emergency setting in resource-limited regions.